News

December 19, 2017

2017 Research Year-in-Review

Over our past fiscal year—from July 1, 2016, to June 30, 2017—Cure SMA has funded 28 projects with over $2.5 million in new research funding. This funding will be used strategically to help accelerate research, and ensure we are developing treatments for all types, ages, and stages of SMA. The areas funded...

READ MORE   |  

Topics: Our Impact, Research, Front Page News

December 18, 2017

Cure SMA Advocates Continue to Advance Newborn Screening Efforts

Cure SMA Advocates Continue to Advance Newborn Screening Efforts

SMA advocates across the country are working tirelessly with Cure SMA to educate state decision makers on newborn screening. In Maryland and Minnesota, the states’ Newborn Screening Advisory Committees voted to approve a recommendation to add SMA to the state panel. We now await final...

READ MORE   |  

Topics: Community & Awareness, Advocacy, Front Page News

December 13, 2017

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

AveXis Announces Plan to Initiate Phase 1 Trial in SMA Type 2 Utilizing Intrathecal Delivery of AVXS-101

AveXis, Inc., a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced...

READ MORE   |  

Topics: Clinical Trials, Research, Front Page News

Items 25 - 27 of 435  Previous12345678910Next

© 2018 Cure SMA | Privacy Policy

Powered by Blackbaud
nonprofit software